CVA Stroke
Conditions
Interventions
TDCS will be applied over the primary motor cortex with 2mA during 90 seconds
(placebo), or with 2mA for 20 minutes (anodal).
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy Age 18-55 yr Intact skin on the scalp
Exclusion criteria
Exclusion criteria: History of neurological or psychiatric disorders Implants or metal parts in the head Use of psychoactive drugs in the last month Pregnancy Left-handedness Skin disease on the scalp, such as eczema
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MEP-amplitude ratio: Measure for brain excitability. The height of the MEP amplitudes will be measured at a constant stimulation intensity. The grand average after TDCS will be divided by the average before TDCS. APLM (latency): Difference in MEP latencies between TMS pulses with an anterior-posterior current direction and lateral-medial current direction. Denoted in milliseconds. BDNF (val66met genotype): non-carrier or met-carrier. Derived from genotyping saliva samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| MAIN1: The MEP-ratio of the first anodal session minus the MEP-ratio of the second placebo session i.e. the main effect in the first measurement pair. MAIN2: The MEP-ratio of the second anodal session minus the MEP-ratio of the second placebo session i.e. the main effect in the second measurement pair. IO-curve ratio: Alternative measure of brain excitability. he height of the MEP amplitudes at a range of stimulation intensities (the input output curve). The average area under the curve after TDCS will be divided by the average before TDCS. | — |
Countries
Netherlands
Outcome results
None listed